Compare McKesson Corporation (MCK) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Rivian Automotive, Inc. — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Rivian Automotive, Inc. trades at $17.32 (market cap $24.95B). The key difference: McKesson Corporation is far larger — about 3.9× Rivian Automotive, Inc.'s market cap, and McKesson Corporation pays a 0.39% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.
| MCK | RIVN | |
|---|---|---|
Market Cap | $97.35B | $24.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $22.45 |
52-Week Low | $659.01 | $11.64 |
Enterprise Value | $101.98B | $26.70B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Rivian Automotive (RIVN) trades at $17.19, down 1.52% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company continues to post significant losses, with a net income margin of -63.62% for 2025, though revenue growth has been steady and recent quarterly EPS have beaten expectations. Cash flow remains negative, but the trend shows improvement from prior years. Analyst sentiment is mixed with a consensus price target of $19.22.
The outlook hinges on successful execution of the R2 vehicle launch and path to profitability. Investment opportunity lies in the potential for market share gains in the EV sector, but risks include high cash burn, competitive pressures, and reliance on capital markets for funding. The stock's performance will be closely tied to quarterly earnings and production updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
